Citations

Mayo Clinic

Showing 10 of 108572 citations.

Faculty Opinions recommendation of Physiological restraint of Bak by Bcl-xL is essential for cell survival.
Kaufmann, Scott H. , Dai, Haiming

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726369624.793525464 Get It

Faculty Opinions recommendation of An interconnected hierarchical model of cell death regulation by the BCL-2 family.
Kaufmann, Scott H. , Dai, Haiming

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725773056.793525463 Get It

Faculty Opinions recommendation of Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores.
Kaufmann, Scott H. , Dai, Haiming

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726084558.793525460 Get It

Faculty Opinions recommendation of Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis.
Kaufmann, Scott H. , Dai, Haiming

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726084556.793525461 Get It

Faculty Opinions recommendation of Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers.
Kaufmann, Scott H. , Dai, Haiming

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 17, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718552096.793525462 Get It

EBV-positive Richter’s syndrome with laboratory features of Burkitt’s lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia
Hussaini, Mohammad , Rehman, Alman, Pinilla‐Ibarz, Javier , Horna, Pedro , Chavez, Julio C

Leukemia & Lymphoma | November 17, 2016 | Volume: 58 | Issue: 7 | Pages: 1753-1756

10.1080/10428194.2016.1256482 | PMID 27852142 Get It

Oesophageal lichen planus: the efficacy of topical steroid‐based therapies
Podboy, Alexander , Sunjaya, Dharma , Smyrk, Thomas C. , Katzka, David A. , Alexander, J.A., Halland, Magnus , Murray, Joseph A. , Binder, Moritz , Alexander, J. A., Sunjaya, D

Alimentary Pharmacology & Therapeutics | November 17, 2016 | Volume: 45 | Issue: 2 | Pages: 310-318

10.1111/apt.13856 | PMID 27859412 Get It

SummaryBackgroundOesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary.AimTo examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus.MethodsA retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7–11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak‐Bennett dysphagia score (0–4, no dysphagia to total aphagia). Pre‐ and post‐endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained.ResultsWe identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0–4) to 0 (0–3) after steroid therapy (P < 0.001) was noted. 62% of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5% had an endoscopic response to steroid therapy.ConclusionTopical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.
Correlation between histopathologic features and likelihood of identifying superficial dermatophytosis with periodic acid Schiff‐diastase staining: a cohort study
Wang, Michael Z. , Guo, Ruifeng , Lehman, Julia S. , Lehman, Julia S , Guo, Ruifeng

Journal of Cutaneous Pathology | November 17, 2016 | Volume: 44 | Issue: 2 | Pages: 152-157

10.1111/cup.12865 | PMID 27859475 Get It

Background Periodic acid Schiff‐diastase ( PAS ‐D) staining is used routinely in dermatopathology. Conventionally, parakeratosis or intracorneal neutrophils justify use of PAS ‐D stain to identify dermatophytosis. We aimed to investigate the histopathological features of superficial dermatophytosis. Methods Skin biopsies with PAS ‐D stain were retrospectively reviewed by a blinded dermatopathologist. Histopathologic findings in cases with dermatophytosis were compared with those without. Results We studied 110 cases, of which 63 were PAS ‐D positive for dermatophytes. Dermatophytes were identified on hematoxylin and eosin (H&E) staining in 49 (77.8%) of the PAS ‐D‐positive cases. Diffuse compact orthokeratosis (79.37%, p < 0.001) and focal parakeratosis (65.08%, p = 0.03) were significantly more frequent in dermatophytosis. Intracorneal neutrophils and spongiosis were not significant findings. Fungal elements were frequently observed within compact orthokeratosis (62.0%) and parakeratosis (31.8%) but rarely within intracorneal pustules (12.7%). In some dermatophyte cases, intracorneal neutrophils (47.6%) or parakeratosis (17.5%) were absent. Conclusions Compact orthokeratosis or focal parakeratosis justifies PAS ‐D staining, whereas the absence of intracorneal neutrophils or parakeratosis is insufficient to exclude dermatophytosis. Results indicate that having a low threshold to perform PAS‐D stain is justified. PAS‐D stain may be deferred until H&E slides have been evaluated.
Shared Decision Making With Vulnerable Populations in the Emergency Department
Castaneda‐Guarderas, Ana, Glassberg, Jeffrey , Grudzen, Corita R. , Ngai, Ka Ming , Samuels‐Kalow, Margaret , Shelton, Erica , Wall, Stephen P. , Richardson, Lynne D.

Academic Emergency Medicine | November 17, 2016 | Volume: 23 | Issue: 12 | Pages: 1410-1416

10.1111/acem.13134 | PMID 27860022 Get It

Abstract The emergency department ( ED ) occupies a unique position within the healthcare system, serving as a safety net for vulnerable patients, regardless of their race, ethnicity, religion, country of origin, sexual orientation, socioeconomic status, or medical diagnosis. Shared decision making ( SDM ) presents special challenges when used with vulnerable population groups. The differing circumstances, needs, and perspectives of vulnerable groups invoke issues of provider bias, disrespect, judgmental attitudes, and lack of cultural competence, as well as patient mistrust and the consequences of their social and economic disenfranchisement. A research agenda that includes community‐engaged approaches, mixed‐methods studies, and cost‐effectiveness analyses is proposed to address the following questions: 1) What are the best processes/formats for SDM among racial, ethnic, cultural, religious, linguistic, social, or otherwise vulnerable groups who experience disadvantage in the healthcare system? 2) What organizational or systemic changes are needed to support SDM in the ED whenever appropriate? 3) What competencies are needed to enable emergency providers to consider patients’ situation/context in an unbiased way? 4) How do we teach these competencies to students and residents? 5) How do we cultivate these competencies in practicing emergency physicians, nurses, and other clinical providers who lack them? The authors also identify the importance of using accurate, group‐specific data to inform risk estimates for SDM decision aids for vulnerable populations and the need for increased ED ‐based care coordination and transitional care management capabilities to create additional care options that align with the needs and preferences of vulnerable populations.
Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial
Stähli, Barbara E. , Duchatelle, Valérie , Cournoyer, Daniel , Petroni, Thibaut, Tanguay, Jean‐François , Robb, Stephen, Mann, Jessica, Guertin, Marie‐Claude , Wright, R. Scott , L’Allier, Philippe L. , Gebhard, Cathérine , Tardif, Jean‐Claude

Journal of the American Heart Association | November 17, 2016 | Volume: 5 | Issue: 11 | Pages: No page available

10.1161/jaha.116.004255 | PMID 27852589 Get It

Background The Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction ( SELECT ‐ ACS ) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on periprocedural myocardial damage. This study evaluated the effect of inclacumab on myocardial damage according to varying time intervals between study drug infusion and percutaneous coronary intervention ( PCI ). Methods and Results Patients (n=544) enrolled in the SELECT ‐ ACS trial and randomized to receive 1 infusion of placebo or inclacumab (5 or 20 mg/kg, administered between 1 and 24 hours before PCI ) were divided according to the time interval between study drug infusion and PCI . The primary end point was the change in troponin I from baseline at 16 and 24 hours after PCI . In patients receiving inclacumab 20 mg/kg with a short (less than median) time interval between infusion and PCI , placebo‐adjusted geometric mean percent changes in troponin I, creatine kinase–myocardial band, and peak troponin I at 24 hours were −45.6% ( P =0.005), −30.7% ( P =0.01), and −37.3% ( P =0.02), respectively. No significant changes were observed in patients with a long (greater than median) time interval between infusion and PCI . Placebo‐adjusted geometric mean percent changes in troponin I and creatine kinase–myocardial band were −43.5% ( P =0.02) and −26.0% ( P =0.07), respectively, when inclacumab 20 mg/kg was administered between 1 and 3 hours before PCI , whereas the drug had no effect with longer intervals. Conclusions Inclacumab 20 mg/kg significantly reduces myocardial damage after PCI in patients with non– ST ‐segment elevation myocardial infarction, and benefits are larger when the infusion is administered <3 hours before PCI . Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01327183.